×
验证码:
换一张
Forgotten Password?
Stay signed in
Login With UMPASS
English
|
繁體
Login With UMPASS
Log In
ALL
ORCID
TI
AU
PY
SU
KW
TY
JN
DA
IN
PB
FP
ST
SM
Study Hall
Image search
Paste the image URL
Home
Faculties & Institutes
Scholars
Publications
Subjects
Statistics
News
Search in the results
Faculties & Institutes
Faculty of Healt... [2]
INSTITUTE OF COL... [1]
Authors
LEUNG LAI HAN [1]
Document Type
Journal article [4]
Date Issued
2023 [2]
2022 [2]
Language
英語English [3]
Source Publication
Frontiers in Onc... [1]
Pharmacological ... [1]
Phytomedicine [1]
Proceedings of t... [1]
Indexed By
SCIE [2]
Funding Organization
Funding Project
×
Knowledge Map
UM
Start a Submission
Submissions
Unclaimed
Claimed
Attach Fulltext
Bookmarks
Browse/Search Results:
1-4 of 4
Help
Selected(
0
)
Clear
Items/Page:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Sort:
Select
Issue Date Ascending
Issue Date Descending
Title Ascending
Title Descending
Author Ascending
Author Descending
WOS Cited Times Ascending
WOS Cited Times Descending
Submit date Ascending
Submit date Descending
Journal Impact Factor Ascending
Journal Impact Factor Descending
Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2
Journal article
Rao, Xia, Zhao, Runchu, Tong, Zhou, Guo, Shuxin, Peng, Weiyu, Liu, Kefang, Li, Shihua, Wu, Lili, Tong, Jianyu, Chai, Yan, Han, Pu, Wang, Feiran, Jia, Peng, Li, Zhaohui, Zhao, Xin, Li, Dedong, Zhang, Rong, Zhang, Xue, Zou, Weiwei, Li, Weiwei, Wang, Qihui, Gao, George Fu, Wu, Yan, Dai, Lianpan, Gao, Feng. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2[J]. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120(52), e2314193120.
Authors:
Rao, Xia
;
Zhao, Runchu
;
Tong, Zhou
;
Guo, Shuxin
;
Peng, Weiyu
; et al.
Favorite
|
TC[WOS]:
8
TC[Scopus]:
9
IF:
9.4
/
10.8
|
Submit date:2024/01/02
Cryptic Epitope
Neutralizing Antibody
Omicron Ba.4/ba.5/bq.1.1/xbb Subvariant
Rbd-8
Sars-cov-2
Formosanin C inhibits non-small-cell lung cancer progression by blocking MCT4/CD147-mediated lactate export
Journal article
Li, Jiaqi, Wu, Zongjin, Chen, Geer, Wang, Xiaoxuan, Zhu, Xiaoyu, Zhang, Yao, Zhang, Ren, Wu, Weiyu, Zhu, Yizhun, Ma, Lijuan, Yu, Haijie. Formosanin C inhibits non-small-cell lung cancer progression by blocking MCT4/CD147-mediated lactate export[J]. Phytomedicine, 2023, 109.
Authors:
Li, Jiaqi
;
Wu, Zongjin
;
Chen, Geer
;
Wang, Xiaoxuan
;
Zhu, Xiaoyu
; et al.
Favorite
|
TC[WOS]:
6
TC[Scopus]:
6
IF:
6.7
/
6.2
|
Submit date:2023/10/26
CD147
Formosanin C (FC)
Lactate
MCT4
NSCLC
Celastrol inhibits lung cancer growth by triggering histone acetylation and acting synergically with HDAC inhibitors
Journal article
Chen, Geer, Zhu, Xiaoyu, Li, Jiaqi, Zhang, Yao, Wang, Xiaoxuan, Zhang, Ren, Qin, Xinchen, Chen, Xi, Wang, Junyi, Liao, Weilin, Wu, Zongjin, Lu, Lu, Wu, Weiyu, Yu, Haijie, Ma, Lijuan. Celastrol inhibits lung cancer growth by triggering histone acetylation and acting synergically with HDAC inhibitors[J]. Pharmacological Research, 2022, 185.
Authors:
Chen, Geer
;
Zhu, Xiaoyu
;
Li, Jiaqi
;
Zhang, Yao
;
Wang, Xiaoxuan
; et al.
Favorite
|
TC[WOS]:
16
TC[Scopus]:
17
IF:
9.1
/
9.0
|
Submit date:2023/01/31
Acetylation
Anacardic ACid (Pubchem Cid: 167551)
C646 (Pubchem Cid: 1285941)
Celastrol
Celastrol (Pubchem Cid: 122724)
Ci994 (Pubchem Cid: 2746)
Hdac
Histone Modification
Lung Cancer
Mc1568 (Pubchem Cid: 71311876)
Ms275 (Pubchem Cid: 4261)
Nu9056 (Pubchem Cid: 72201043)
Saha (Pubchem Cid: 5311)
The key role of sphingolipid metabolism in cancer: New therapeutic targets, diagnostic and prognostic values, and anti-tumor immunotherapy resistance
Journal article
Li RunZe, Wang XuanRun, Wang Jian, Xie Chun, Wang XingXia, Pan HuDan, Meng WeiYu, Liang TuLiang, Li JiaXin, Yan PeiYu, Wu QiBiao, Liu Liang, Yao XiaoJun, Leung Elaine Lai Han. The key role of sphingolipid metabolism in cancer: New therapeutic targets, diagnostic and prognostic values, and anti-tumor immunotherapy resistance[J]. Frontiers in Oncology, 2022.
Authors:
Li RunZe
;
Wang XuanRun
;
Wang Jian
;
Xie Chun
;
Wang XingXia
; et al.
Favorite
|
IF:
3.5
/
4.0
|
Submit date:2023/06/15